Holen Sie sich die Stockscreener-App
83.75
0.35%
-0.29
Haemonetics Corp Aktie (HAE) Neueste Nachrichten
Irish medtech Vivasure sold in €185m deal to US-listed Haemonetics - Business Post
BTIG Reiterates Buy Rating for Haemonetics (HAE) at $88 Price Ta - GuruFocus
Haemonetics Expands Heart Surgery Arsenal With Vivasure Acquisition - Benzinga
Irish maker of dissolving vessel-closure implant sold in €185M deal - Stock Titan
Haemonetics (HAE) Acquires Vivasure Medical for €100M - GuruFocus
Haemonetics acquires Vivasure to expand structural heart portfolio - TipRanks
Haemonetics Acquires Vivasure Medical - Nasdaq
Haemonetics Corp Acquires Vivasure Medical Limited - TradingView — Track All Markets
New dissolving patch seals blood vessels after heart procedures - Stock Titan
Why Haemonetics Corporation stock is considered a top pick2025 Trading Recap & Fast Entry High Yield Tips - ulpravda.ru
Why Haemonetics Corporation (HAZ) stock remains stableJuly 2025 Big Picture & Daily Profit Focused Screening - ulpravda.ru
Plasmapheresis Machines Market Outlook 2025: Expanding - openPR.com
Haemonetics sets Feb. 5 date to share its third‑quarter results - Stock Titan
Baird Maintains Haemonetics(HAE.US) With Buy Rating, Maintains Target Price $99 - 富途牛牛
Is Haemonetics (NYSE:HAE) Using Too Much Debt? - 富途牛牛
Haemonetics Corporation (HAE) Stock Analysis: Insights into a Promising Medical Device Leader with a 9.85% Upside - DirectorsTalk Interviews
These 4 Measures Indicate That Haemonetics (NYSE:HAE) Is Using Debt Reasonably Well - simplywall.st
Haemonetics to Present at 44th Annual J.P. Morgan Healthcare Conference - MarketScreener
Hear Haemonetics' CEO live at J.P. Morgan Healthcare Conference online - Stock Titan
Allspring Global Investments Holdings LLC Boosts Holdings in Haemonetics Corporation $HAE - MarketBeat
Haemonetics Corporation (NYSE:HAE) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Fort Washington Investment Advisors Inc. OH Has $34.43 Million Stock Holdings in Haemonetics Corporation $HAE - MarketBeat
Haemonetics Corporation $HAE Shares Sold by Boston Trust Walden Corp - MarketBeat
Haemonetics Corporation: The Vascular Closure Comeback Plan—Can VASCADE Reaccelerate Growth? - Smartkarma
Intuitive Surgical downgraded as Citi previews 2026 in MedTech - MSN
Harbor Capital Advisors Inc. Purchases 14,226 Shares of Haemonetics Corporation $HAE - MarketBeat
Do You Believe in the Long-Term Growth Potential of Haemonetics Corporation (HAE)? - Yahoo Finance
Aug PostEarnings: What risks investors should watch in Haemonetics Corporation stockJuly 2025 Action & AI Forecast for Swing Trade Picks - moha.gov.vn
Mizuho Securities Maintains Haemonetics(HAE.US) With Buy Rating, Raises Target Price to $90 - 富途牛牛
Haemonetics Is Maintained at Outperform by Mizuho - 富途牛牛
Will Haemonetics Corporation stock profit from AI boomMarket Performance Report & Precise Buy Zone Identification - Улправда
Assenagon Asset Management S.A. Invests $8.56 Million in Haemonetics Corporation $HAE - MarketBeat
Is it apt to retain Haemonetics stock in your portfolio now? - MSN
Haemonetics (FRA:HAZ) EV-to-OCF : 15.32 (As of Dec. 19, 2025) - GuruFocus
Here's Why Haemonetics (HAE) is a Strong Growth Stock - Yahoo Finance
Why Haemonetics Corporation (HAZ) stock could rally stronglyWeekly Risk Summary & AI Powered Buy/Sell Recommendations - DonanımHaber
What risks investors should watch in Haemonetics Corporation stockBull Run & Safe Entry Momentum Tips - Улправда
MACD Signal: Is Haemonetics Corporation stock in correction or buying zoneDollar Strength & Daily Growth Stock Investment Tips - Улправда
Haemonetics (HAE) Valuation Check After Needham Downgrade on Rising Vascular Closure Competition - simplywall.st
Haemonetics Expands Medical Solutions Across Global Healthcare - Kalkine Media
Haemonetics (NYSE:HAE) Price Target Raised to $90.00 - MarketBeat
HAE Receives Rating Update from Mizuho with Raised Price Target - GuruFocus
Haemonetics price target raised to $90 from $75 at Mizuho - TipRanks
Should Competitive Pressure In Vascular Closure Devices Prompt a Reassessment by Haemonetics (HAE) Investors? - Yahoo Finance
Riverwater Partners Small Cap Strategy Sold Its Stake in Haemonetics Corporation (HAE) in Q3 - Yahoo Finance
Haemonetics Sets Date for Publishing Fourth Quarter and Fiscal Year 2025 Results: May 8, 2025 - 富途牛牛
Haemonetics (HAE) Downgraded by Needham Amid Competition Concerns - GuruFocus
Haemonetics downgraded to Hold from Buy at Needham - TipRanks
HAE: Baird Raises Price Target to $99, Rating Remains Outperform - GuruFocus
Why Haemonetics Shares Are Facing Turbulence - TipRanks
Why Haemonetics (HAE) Shares Are Trading Lower Today - Yahoo Finance
Here's Why Haemonetics (HAE) is a Strong Momentum Stock - Yahoo Finance
Haemonetics price target raised to $99 from $87 at Baird - TipRanks
Needham downgrades Haemonetics stock to Hold on vascular closure device competition concerns - Investing.com
Needham Downgrades Haemonetics to Hold From Buy, Removes $78 Price Target - marketscreener.com
HAE Downgraded to Hold by Needham in Recent Ratings Update | HAE Stock News - GuruFocus
Needham Downgrades Haemonetics(HAE.US) to Hold Rating - 富途牛牛
ETFs investiert in Haemonetics Corporation-AktienTradingView - TradingView - Alle Märkte im Blick
Haemonetics (NYSE:HAE) Stock Rating Lowered by Wall Street Zen - MarketBeat
Haemonetics (NYSE:HAE) Price Target Raised to $74.00 at JPMorgan Chase & Co. - MarketBeat
JP Morgan Maintains Haemonetics (HAE) Neutral Recommendation - MSN
Haemonetics (HAE) Receives Updated Neutral Rating with Raised Pr - GuruFocus
Haemonetics price target raised to $74 from $62 at JPMorgan - TipRanks
Is it Apt to Retain Haemonetics Stock in Your Portfolio Now? - Yahoo Finance
Citi downgrades Haemonetics (HAE) to a Hold - The Globe and Mail
Why Haemonetics (HAE) Stock Is Down Today - Finviz
0.54%
0.24%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):